Pre-Open Movers 04/02: (SLS) (MNOV) (CVLT) Higher; (ALKS) (SORL) (ITCI) Lower (more...)
- Wall Street ends mixed; Salesforce selloff pressures Dow
- Ulta Beauty (ULTA) raises FY22 outlook, tops earnings, revenue estimates
- S&P 500 to re-test lows in H1 and then rally to 4200 on Fed pivot signal - JPMorgan
- Zscaler shares plunge 11% despite Q1 & guidance beat
- Salesforce (CRM) drops after soft results, MS sees attractive valuation
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Today's Pre-Open Movers
SELLAS Life Sciences Group Inc., (Nasdaq: SLS) 44.9% HIGHER; announced positive interim data from the prospective, randomized, single-blinded, controlled Phase 2b independent investigator-sponsored clinical trial (IST) of trastuzumab (Herceptin®) +/- nelipepimut-S (NeuVax) in HER2 1+/2+ breast cancer patients in the adjuvant setting to prevent recurrences.
MediciNova, Inc. (NASDAQ: MNOV) 27.2% HIGHER; announced that it will terminate the Phase 2 clinical trial of MN-001 (tipelukast) in NASH (non-alcoholic steatohepatitis) and NAFLD (non-alcoholic fatty liver disease) with hypertriglyceridemia early based on the significant positive results from an interim analysis.
Alkermes plc (Nasdaq: ALKS) 19.4% LOWER; received a Refusal to File letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressant therapies.
Sorl Auto Parts (NASDAQ: SORL) 16.3% LOWER; reported Q4 EPS of $0.15, versus $0.47 reported last year. Revenue for the quarter came in at $123 million versus the consensus estimate of $103.59 million.
Compugen Ltd. (NASDAQ: CGEN) 12.4% HIGHER; announced it entered into an exclusive license agreement with MedImmune, the global biologics research and development arm of AstraZeneca (NYSE: AZN), to enable the development of bi-specific and multi-specific immuno-oncology antibody products.
Commvault Systems, Inc. (NASDAQ: CVLT) 9.6% HIGHER; Elliott Management disclosed a 10.3% and released a letter announcing its intention to nominate four highly qualified candidates to the Commvault Board.
Intra-Cellular Therapies (NASDAQ: ITCI) 6.9% LOWER; down on ALKS news
Senseonics Holdings, Inc. (NYSE: SENS) 5.7% HIGHER; announced a favorable outcome of the U.S. Food and Drug Administration (FDA) Clinical Chemistry and Clinical Toxicology Devices meeting on the Eversense system. The panel, comprised of independent medical experts, voted unanimously, 8 to 0, that the benefits outweigh the risks, voted unanimously, 8 to 0, that the system is safe, and voted unanimously, 8 to 0, that the system is effective.
Fitbit (NYSE: FIT) 4.1% LOWER; Morgan Stanley downgraded from Equalweight to Underweight with a price target of $4.00 (from $5.00).
Tesla (NASDAQ: TSLA) 3.9% LOWER; Musk jokes about bankruptcy in a tweet, continued worries about AutoPilot and cautious ahead of Model 3 numbers.
Amazon (NASDAQ: AMZN) 2% LOWER; President Trump escalates attacks.
Northern Trust (NASDAQ: NTRS) 1% HIGHER; Goldman Sachs upgraded from Neutral to Buy with a price target of $121.00 (from $113.00).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla (TSLA) recalls 435,000 EVs in China over marker light issue
- CrowdStrike (CRWD) plunges 20% after 'messy' and 'disappointing' results
- Snowflake (SNOW) falls as macro headwinds drag on guidance, analysts remain upbeat
Create E-mail Alert Related CategoriesSpecial Reports
Related EntitiesGoldman Sachs, The Children's Investment Fund (TCI), Morgan Stanley, Elliott Associates, Tesla, Pre-Open Losers, Pre-Open Winners, Pre Market Movers, Model 3, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!